Back to Search Start Over

297 Chemoimmunotherapy with weekly cisplatin and etoposide plus S.C. rIL-2 plus oral medroxyprogesterone acetate (MPA) in stage IIIB-IV NSCLC: Preliminary results on clinical response and on immunologic assessment